Document:

kl09037_ex4-18.htm

 

    
      

    

     

    Exhibit 4.18

     

     

    
      FINDERS
AGREEMENT

      

      This
Agreement is dated effective as of July 1, 2009.

      

      BETWEEN:

      

      HELIX BIOPHARMA CORP. having
an office at 3-305 Industrial Parkway South, Aurora, Ontario, Canada
(hereinafter referred to as "Helix")

      

      AND:

      

      ACM ALPHA CONSULTING MANAGEMENT EST.
having an office at St. Markusgasse 27 A, 9490 Vaduz,, Liechtenstein
(hereinafter referred to as “ACM”)

       

      WHEREAS this Agreement is to
confirm the agreement of the parties regarding finder’s fees which may be
payable to ACM in respect of private placements by Helix of securities to
accredited investors, not residents of Canada or the United States, introduced
to Helix by ACM;

      

      NOW THEREFORE in consideration
of the sum of One Dollar now paid by each party to the other, and other good and
valuable consideration, the receipt and adequacy of which are hereby
acknowledged by the parties, the parties hereby covenant and agree as
follows:

       

      
        	
                (1)  

              	
                Helix
      hereby engages ACM to find and introduce to Helix potential investors
      (“Investors”), not residents of Canada or the United States, in respect of
      private placements (“Placements”) by Helix of its securities
      (“Securities”). ACM will only find and introduce to Helix Investors who
      fit within the definition of an “accredited investor”, as set out in
      Schedule “A” attached.

              

      

      

      
        	
                (2)  

              	
                It
      is mutually agreed and understood that Helix will be responsible for all
      information, statements, and representations made and for any descriptive
      information regarding Helix prepared and contained in any information
      provided by Helix to ACM.

              

      

      

      
        	
                (3)  

              	
                ACM
      will provide Helix with the names and contact information of any potential
      Investors.  Helix will then advise ACM whether the potential
      Investor has already been introduced to Helix, or whether such potential
      Investor may be an “ACM Contacted Investor” for purposes of this
      Agreement.

              

      

      

      
        	
                (4)  

              	
                Should
      an ACM Contacted Investor successfully complete a Placement with Helix
      within six months of such investor being disclosed to Helix by ACM, then
      ACM shall have earned and be entitled to a fee equal to 12.5% of the funds
      raised.  Such fee shall be payable to ACM within 10 business
      days following the closing of the Placement, and the receipt by Helix of
      the gross proceeds of the
Placement.

              

      

      

      
        	
                (5)  

              	
                Helix
      represents and warrants to ACM that it is a corporation duly organized,
      validly existing and in good standing under the laws of Canada, that it
      has the corporate power to execute, deliver and perform its obligations
      under this Agreement, that the execution, delivery and performance of this
      Agreement have been duly authorized by all necessary corporate action on
      its part and that this Agreement constitutes its legal, valid and binding
      obligation, enforceable against it in accordance with its
      terms.  ACM represents and warrants to Helix that it is a
      corporation duly organized, validly existing and in good standing under
      the laws of Liechtenstein, that it has the corporate power to execute,
      deliver and perform its obligations under this Agreement, that the
      execution, delivery and performance of this Agreement have been duly
      authorized by all necessary corporate action on its part and that this
      Agreement constitutes its legal, valid and binding obligation, enforceable
      against it in accordance with its
terms.

              

      

       

       

       

      
        
          
          

        

        
          
          

          
            

          

        

        
          
          

        

      

      
 

      
        	
                (6)  

              	
                ACM
      further represents and warrants to Helix that (i) ACM has been duly
      licensed, registered, or otherwise officially recognized or approved as
      required by applicable law in all jurisdictions where ACM does or intends
      to do business, including all jurisdictions in which ACM may contact
      Investors, such that ACM may lawfully carry out the transactions
      contemplated by this Agreement; and (ii) neither the entering into of this
      Agreement or the transactions contemplated hereby will violate any law
      applicable to ACM nor constitute a violation of, or, with or without
      notice or lapse of time or both, a default under, or conflict with, any
      other agreement, document or instrument to which ACM is a party or by
      which ACM or any of ACM’s property may be
bound.

              

      

      

      
        	
                (7)  

              	
                ACM
      acknowledges that this Agreement and any fee ultimately payable to ACM may
      be subject to approval of such regulatory authorities as may have
      jurisdiction over Helix and the Placements, including The Toronto Stock
      Exchange (“TSX”).

              

      

      

      
        	
                (8)  

              	
                The
      terms and conditions of the Placements and the acceptance thereof will be
      in the sole and exclusive discretion of
Helix.

              

      

      

      
        	
                (9)  

              	
                ACM
      will only contact ACM Contacted Investors for purposes of this Agreement,
      and will only provide and disclose to ACM Contacted Investors, information
      which has been approved by Helix and ACM will ensure that any ACM
      Contacted Investor is provided with any new or updated information
      provided to ACM by Helix on a timely
basis.

              

      

      

      
        	
                (10)  

              	
                ACM
      acknowledges that ACM Contacted Investors are only to be Investors who are
      not residents of Canada or the United States and who are purchasing for
      their own account and not for the benefit of any resident of Canada or of
      the United
States.  Accordingly:

              

      

      

      
        	
                (a)  

              	
                ACM
      will only contact ACM Contacted Investors who it reasonably believes to be
      resident of a country other than Canada or the United States who are
      purchasing for their own account;

              

      

      

      
        	
                (b)  

              	
                If
      an ACM Contacted Investor provides a signed subscription agreement to
      Helix, ACM will, at the request of Helix, provide Helix with its
      certificate that the subscriber (or the beneficial purchaser, if the
      subscriber is a bank, trust company, brokerage firm, or other person
      acting as agent for a beneficial purchaser) is neither directly nor
      indirectly a resident or citizen of or incorporated in Canada or the
      United States and is not subscribing on behalf of any resident or citizen
      or corporation of Canada or of the United
  States.

              

      

      

      
        	
                (11)  

              	
                ACM
      may have access to information belonging to Helix that is confidential and
      proprietary in nature.  ACM agrees that all such information
      will be kept in confidence and will be dealt with only in accordance with
      the Confidentiality Agreement dated as of July 1, 2009 between Helix and
      ACM.  ACM further acknowledges and agrees that nothing in this
      Agreement or such Confidentiality Agreement permits ACM to disclose any of
      such confidential information to any Investor, which disclosure is
      strictly prohibited.

              

      

      

      
        	
                (12)  

              	
                ACM
      agrees that at all times in its dealings with ACM Contacted Investors, and
      otherwise in connection with Helix, it will not offer any securities or
      take any other action which would result in either ACM or Helix being
      required to file or deliver a prospectus or any other form of offering
      document under any applicable law, and it will comply with all applicable
      laws and regulatory policies, including without limitation, securities
      laws and policies and all applicable rules, regulations and policies of
      the TSX and any other stock exchange on which the shares of Helix are or
      may hereafter be listed.  Without limiting the generality of the
      foregoing, ACM will not make any written or oral representations to any
      ACM Contacted Investor:

              

      

       

       

       

      
        
          
          

        

        
          2

          
            

          

        

        
          
          

        

      

       

      
         

        
          	
                   
      

                	
                  (i)

                	
                  that
      any person will resell or repurchase the
  Securities;

                

        

        
        

         

        
          	
                   
      

                	
                  (ii)

                	
                  
                    that
      any person will refund, or provide a guarantee against loss of, the
      purchase price or value of the
Securities;

                  

                

        

         

      

      
        	
                 
      

              	
                (iii)

              	
                as
      to the future price or value of any of the Securities;
  or

              

      

       

      
        	
                 
      

              	
                (iv)

              	
                that
      the Securities will be listed and posted for trading on a stock exchange
      or that application has been made to list and post the Securities for
      trading on a stock exchange, other than the
TSX.

              

      

      

      
        	
                (13)  

              	
                Subject
      to paragraph (16), Helix shall pay to ACM a fixed monthly amount of 30,000
      swiss francs to cover all of ACM’s reasonable out-of-pocket expenses
      incurred in connection with its obligations hereunder.  Such
      monthly amount shall be payable within 30 days following receipt of an
      invoice from ACM in form and content reasonably acceptable to Helix,
      together with such back-up documentation as Helix may reasonably require.
      Any expenses incurred by ACM in any month in excess of 30,000 swiss francs
      shall be for ACM’s own account and shall not be reimbursed by
      Helix.  

              

      

      

      
        	
                (14)  

              	
                ACM
      shall not, and shall cause its directors, officers, employees, agents, and
      partners  (if any) to not, directly or indirectly, buy, sell,
      borrow, pledge, or otherwise trade in any securities of Helix commencing
      from the date hereof until the expiry of 48 hours after Helix issues a
      news release disclosing the last of any private placements of Helix
      securities, in respect of which ACM is entitled to receive a finders fee
      pursuant to this Agreement.

              

      

      

      
        	
                (15)  

              	
                This
      Agreement and the services provided by ACM in connection with the
      transactions contemplated herein shall be governed by and construed in
      accordance with the laws of the Province of
  Ontario.

              

      

      

      
        	
                (16)  

              	
                This
      Agreement shall terminate on December 31, 2009.  Notwithstanding
      the foregoing, either party may terminate this Agreement upon 30 days’
      written notice to the other.  Any fees which have been earned
      but have not been paid prior to termination shall remain payable. The
      monthly expense amount otherwise payable pursuant to Paragraph (13) in
      respect of the month in which notice of termination is given (the
      “termination month”) shall be pro-rated, with the proportion of such
      amount payable being equal to the proportion that the number of days in
      the termination month leading up to and including the date notice of
      termination is given is to the total number of such days in the
      termination month. No expense amount shall be payable in respect of any
      month following the termination month.  Paragraph (11) of this
      Agreement shall survive termination of this
  Agreement.

              

      

       
 

      Executed
as of the day and year first set forth above.

      

      HELIX
BIOPHARMA CORP.

       

      
      

       

      
        	Per:	___________________________________
	 	Donald H. Segal,
      Chairman and CEO
	 	 
	Per: 	___________________________________
	 	John Docherty,
      President and COO
	 	 

      

       

      ACM
ALPHA CONSULTING MANAGEMENT EST.

      

      
        	Per:	___________________________________
	 	Andreas
      Kandziora

      

       

       

       

      
        
          
          

        

        
          3

          
            

          

        

        
          
          

        

      

       

      
 

      

      SCHEDULE
“A” TO FINDERS AGREEMENT BETWEEN

      HELIX
BIOPHARMA CORP. AND ACM ALPHA CONSULTING MANAGEMENT EST.

      DATED
JULY 1, 2009

      

      

      

      Definitions and Deeming
Provisions

      

      For
purposes of this Schedule “A”, the following definitions and deeming provisions
shall apply:

      

      affiliates — An issuer shall
be deemed to be an affiliate of another issuer if one of them is the subsidiary
of the other or if each of them is controlled by the same person.

      

      beneficial ownership of
securities — A person (first person) shall be deemed to own beneficially
securities beneficially owned by a person (second person) controlled by the
first person or by an affiliate of the second person.  An issuer shall
be deemed to own beneficially securities beneficially owned by its
affiliates.

      

      control of person or company
—  A person (first person) is considered to control another person
(second person), if:

      

       (a)
the first person beneficially owns or directly or indirectly exercises control
or direction over securities of the second person carrying votes which, if
exercised, would entitle the first person to elect a majority of the directors
of the second person, unless the first person holds the voting securities only
to secure an obligation;

      

       (b)
the second person is a partnership, other than a limited partnership, and the
first person holds more than 50 per cent of the interests of the partnership;
or

      

       (c)
the second person is a limited partnership and the general partner of the
limited partnership is the first person or company.

      

      issuer — means a person who
has outstanding, issues or proposes to issue, a security.

      

      person —  means (i)
an individual, (ii) a corporation, (iii) a partnership, trust, fund and an
association, syndicate, organization, or other organized group of persons,
whether incorporated or not, and (iv) an individual or other person in that
person’s capacity as a trustee, executor, administrator, or other legal
representative.

      

      spouse -  means an
individual who is married to another individual and is not living separate and
apart within the meaning of the Divorce Act (Canada), from
the other individual, or who is living with another individual in a
marriage-like relationship;

      

      subsidiary — means an issuer
that is controlled directly or indirectly by another issuer and includes a
subsidiary of that subsidiary;

       

      
 

      
        
           

        

        
          4

          
            

          

        

        
           

        

      

      

      

      Accredited
Investor

      

      An
“accredited investor" means a person who is:

      

      1. An
individual who, either alone or with a spouse, beneficially owns, directly or
indirectly, financial assets (being cash, securities, or a contract of
insurance, a deposit or an evidence of a deposit that is not a security for the
purposes of any Canadian securities legislation) having an aggregate realizable
value that before taxes, but net of any related liabilities (being liabilities
incurred or assumed for the purpose of financing the acquisition or ownership of
financial assets, or liabilities that are secured by financial assets) exceeds
$1,000,000;

      

      2. An
individual whose net income before taxes exceeded $200,000 in each of the 2 most
recent calendar years or whose net income before taxes combined with that of a
spouse exceeded $300,000 in each of the 2 most recent calendar years and who, in
either case, reasonably expects to exceed that net income level in the current
calendar year;

      

      3. An
individual who, either alone or with a spouse, has net assets of at least
$5,000,000;

      

      4. A person,
other than an individual or investment fund, that has net assets of at least
$5,000,000 as shown on its most recently prepared financial statements, but has
not been created or used solely to purchase or hold securities as such an
accredited investor; or

      

      5. A person
in respect of which all of the owners of interests, direct, indirect or
beneficial, except the voting securities required by law to be owned by
directors, are persons that are described in paragraphs 1, 2, 3 or 4
above.

      

      

      [END OF
SCHEDULE “A”]

       

       

       

      5kl09037_ex4-19.htm

 

    
      

    

     

    Exhibit
4.19

     

     

     

    RIVEX PHARMA INC.

    A DIVISION OF HELIX
BIOPHARMA CORP.

     

    3 - 305 Industrial Parkway S.

    Aurora, Ontario

    Canada L4G 6X7

    Tel: (905) 841-2300

    Fax: (905) 841-2244

     

     

     

    July 25,
1997

    

    

    STRICTLY
PRIVATE

    

    William
H. Chick

    29 Beatty
Cr.

    Aurora,
Ontario

    L4G
5V3

    

    Dear
Bill:

    

    We are
delighted at your decision to join our group, and very much look forward to
having you on our management team as we build this business.

    

    The
following will confirm our understanding regarding the terms and conditions of
your employment.

    

    Title:
Vice President, Sales and Marketing, Rivex Pharma Inc.

    

    
      	
              ·  

            	
              Base
      Salary: $110,000

            

    

    

    
      	
              ·  

            	
              Performance
      and salary reviews will take place annually on your
      anniversary

            

    

    

    
      	
              ·  

            	
              Performance
      compensation: You will receive 1.5% of the first $1.5M of the gross sales
      of Rivex, and 1% on the next $1M
      gross sales. This performance compensation will be paid to you on a
      regular basis throughout the year, probably
  quarterly

            

    

    

    
      	
              ·  

            	
              Share
      options: you will receive 75,000 share options of Helix BioPharma Corp. on
      joining our group, at the option price of approximately $2.00 (The option
      price is presently under discussion with the hope of having it
      lowered)

            

    

    

    
      	
              ·  

            	
              Additional
      share options may be available in the future, and you will receive options
      in this same proportion to options being received by other senior
      management

            

    

    

    
      	
              ·  

            	
              Monthly
      car allowance: $500. This is subject to future review. The Company will
      also provide a credit card

            

    

    

    
      	
              ·  

            	
              You
      will be immediately eligible for enrollment in the Company's standard
      benefits program

            

    

    

    

    
      
        
        

      

      
        
        

        
          

        

      

      
        
        

      

    

    

    

    
      	
              ·  

            	
              Vacation:
      4 weeks annually

            

    

    

    
      	
              ·  

            	
              Should
      your employment be terminated for reasons other than just cause, you will
      be given 9 months written notice, or payment equal to 9 months
      salary

            

    

    

    
      	
              ·  

            	
              Start
      date: August 25 or earlier

            

    

    

    Once
again, Bill, we are very pleased to have you on our team. We believe that you
have the background, experience and entrepreneurial style to make a significant
contribution to the growth and performance of Rivex. We look forward to working
with you.

    

    

    Best
Regards,

    

    “Donald
H. Segal”

    

    Donald H.
Segal

    President

    

                                                        “W.
Chick”

                                                      _____________________

                                                             
Accepted

    
      

                                                          July 31,
1997

                                                        _____________________

                                                                       
Date

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00164-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00164-of-00352.parquet"}]]